Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05267821 · ClinicalTrials.gov registry record · Phase 2
Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS
A Phase 2 study of Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS), sponsored by Nationwide Children's Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 500
- Enrollment target
- 20
- Study locations
NCT05267821 is a Phase 2 study of Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS) that is actively recruiting participants, run by Nationwide Children's Hospital. The registered enrollment target is 500 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT05267821, a Phase 2 study of Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS), is actively recruiting participants, sponsored by Nationwide Children's Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 500 participants
- Enrollment target
- 20
- Study locations
Study Summary
The TRIPS study is a prospective, multi-center, double-blind, adaptively randomized, placebo-controlled clinical trial of the drug anakinra for reversal of moderate to severe hyperinflammation in children with sepsis-induced multiple organ dysfunction syndrome (MODS).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Anakinra
Study Locations (20)
California
- Children's Hospital of Los Angeles - Los Angeles
- Benioff Children's Hospital - Oakland - Oakland
- Children's Hospital of Orange County - Orange
- University of California, Davis - Sacramento
- Rady Children's Hospital - San Diego
- Benioff Children's Hospital - Mission Bay - San Francisco
Michigan
- CS Mott Children's Hospital - Ann Arbor
- Children's Hospital of Michigan - Detroit
Minnesota
- Children's Hospital of Minnesota - Minneapolis
- University of Minnesota - Minneapolis
Ohio
- Akron Children's Hospital - Akron
- Cincinnati Children's Hospital Medical Center - Cincinnati
Alabama
- Children's of Alabama - Birmingham
Arkansas
- Arkansas Children's Hospital - Little Rock
Colorado
- Children's Hospital Colorado - Aurora
District of Columbia
- Children's National Medical Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2022-06-14 |
| Est. Completion | 2028-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05267821
The ClinicalTrials.gov registry entry for NCT05267821 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nationwide Children's Hospital, which has 188 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05267821 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Michigan, Minnesota.
Frequently Asked Questions
What is clinical trial NCT05267821 about?
NCT05267821 is a clinical study titled "Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS". The TRIPS study is a prospective, multi-center, double-blind, adaptively randomized, placebo-controlled clinical trial of the drug anakinra for reversal of moderate to severe hyperinflammation in children with sepsis-induced multiple organ dysfunction syndrome (MODS).
What is the current status of trial NCT05267821?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 500 participants. The study started on 2022-06-14. Estimated completion is 2028-08-31.
What conditions does trial NCT05267821 study?
This clinical trial studies the following conditions: Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS).
What interventions are being tested in trial NCT05267821?
The interventions under investigation include: Placebo (DRUG), Anakinra (DRUG).
Who is sponsoring clinical trial NCT05267821?
This trial is sponsored by Nationwide Children's Hospital, which has 188 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05267821 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.